Saleem Benazir, Brown Andrew K, Keen Helen, Nizam Sharmin, Freeston Jane, Karim Zunaid, Quinn Mark, Wakefield Richard, Hensor Elizabeth, Conaghan Philip G, Emery Paul
University of Leeds, Chapel Allerton Hospital, Leeds, UK.
Arthritis Rheum. 2009 Jul;60(7):1915-22. doi: 10.1002/art.24596.
For patients with rheumatoid arthritis (RA) in remission who are receiving disease-modifying antirheumatic drugs (DMARDs), radiographic progression correlates with imaging-detected synovitis as measured by power Doppler activity. In contrast, patients with disease in remission who are receiving the combination of tumor necrosis factor (TNF) blockade with methotrexate (MTX) (combination treatment) have reduced radiographic damage for the equivalent clinical state. We undertook this study to determine whether the difference in radiographic outcome is a result of more complete suppression of imaging-detected synovitis.
One hundred patients with RA in remission (Disease Activity Score in 28 joints [DAS28] <2.6) for at least 6 months while receiving either combination treatment (n = 50) or DMARDs (n = 50) were matched for clinical variables. Ultrasound of metacarpophalangeal joints 1-5 and the wrist joints was performed. Remission according to imaging results was defined as a score of 0 for both grey scale synovitis and power Doppler activity.
In patients receiving combination treatment or DMARDs (median DAS28 1.65 versus 1.78, median disease duration 120 months versus 90 months, and median duration of remission 13 months versus 18 months), the proportion with remission according to imaging results was not significantly different (10% versus 16%, respectively). The combination treatment group had more grey scale synovitis (P < 0.001) but similar power Doppler activity (48% versus 60%, respectively; P = 0.229) in any joint as compared with the DMARD group. Results were not affected by stratification for duration of disease or remission.
In RA patients with disease in remission, imaging-detected synovitis persists, with power Doppler activity seen in >or=48% of the patients regardless of therapy. These results suggest that superior radiographic outcomes in patients treated with the combination of TNF blockade and MTX may not be due to complete suppression of imaging-detected synovitis.
对于正在接受改善病情抗风湿药物(DMARDs)治疗且病情处于缓解期的类风湿关节炎(RA)患者,放射学进展与通过能量多普勒活动测量的影像学检测到的滑膜炎相关。相比之下,接受肿瘤坏死因子(TNF)阻断剂与甲氨蝶呤(MTX)联合治疗(联合治疗)且病情处于缓解期的患者,在同等临床状态下放射学损伤减少。我们开展这项研究以确定放射学结果的差异是否是由于对影像学检测到的滑膜炎更完全的抑制所致。
100例病情处于缓解期(28个关节疾病活动评分[DAS28]<2.6)至少6个月的RA患者,在接受联合治疗(n = 50)或DMARDs(n = 50)时,根据临床变量进行匹配。对第1 - 5掌指关节和腕关节进行超声检查。根据影像学结果,缓解定义为灰阶滑膜炎和能量多普勒活动评分为0。
接受联合治疗或DMARDs的患者(DAS28中位数分别为1.65和1.78,疾病持续时间中位数分别为120个月和90个月,缓解持续时间中位数分别为13个月和18个月),根据影像学结果达到缓解的比例无显著差异(分别为10%和16%)。与DMARD组相比,联合治疗组在任何关节的灰阶滑膜炎更多(P < 0.001),但能量多普勒活动相似(分别为48%和60%;P = 0.229)。结果不受疾病持续时间或缓解分层的影响。
在病情处于缓解期的RA患者中,影像学检测到的滑膜炎持续存在,无论采用何种治疗,≥48%的患者存在能量多普勒活动。这些结果表明,TNF阻断剂与MTX联合治疗的患者放射学结果更好可能并非由于完全抑制了影像学检测到的滑膜炎。